Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 4:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,140 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PET/Computed Tomography (CT) Clear all
Recruiting Phase 2 Interventional

Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T

NCT06784726
View directory record Official record
Conditions
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Odronextamab, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Chimeric Antigen Receptor T-Cell Therapy, Computed Tomography, Leukapheresis, Lumbar Puncture, Positron Emission Tomography, Questionnaire Administration, Biopsy Procedure
Biological · Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 4, 2026, 4:54 PM EDT
Recruiting Phase 1 Interventional

Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations

NCT06043713
View directory record Official record
Conditions
Metastatic Malignant Solid Neoplasm
Interventions
Bendamustine, Biopsy, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Echocardiography, Fludarabine, Leukapheresis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Positron Emission Tomography, T-cell Receptor-engineered T-cells
Drug · Procedure · Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 4, 2026, 4:54 PM EDT
Terminated No phase listed Observational

Liquid Biopsy With PET/CT Versus PET/CT Alone in Diagnosis of Small Lung Nodules

NCT05066776
View directory record Official record
Conditions
Lung Cancer, Solitary Pulmonary Nodule, Multiple Pulmonary Nodules
Interventions
Not listed
Lead sponsor
Palo Alto Veterans Institute for Research
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Dec 8, 2023 · Synced Oct 4, 2026, 4:54 PM EDT
Active, not recruiting Phase 3 Interventional

Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer

NCT03811015
View directory record Official record
Conditions
Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Interventions
Biospecimen Collection, Cisplatin, Computed Tomography, Echocardiography Test, Fludeoxyglucose F-18, Intensity-Modulated Radiation Therapy, Nivolumab, Patient Observation, Positron Emission Tomography
Procedure · Drug · Other + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
636 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
727
States / cities
Fairhope, Alabama • Mobile, Alabama • Anchorage, Alaska + 462 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 4, 2026, 4:54 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

NCT01896999
View directory record Official record
Conditions
Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
Interventions
Biopsy Procedure, Biospecimen Collection, Brentuximab Vedotin, Computed Tomography, Ipilimumab, Nivolumab, Positron Emission Tomography
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
479
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 303 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 4, 2026, 4:54 PM EDT
Completed No phase listed Observational

Motion Correction of Positron Emission Tomography (PET) Data Using Amplitude Gating

NCT00843219
View directory record Official record
Conditions
Lung Cancer
Interventions
PET/CT Scan
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Oct 4, 2026, 4:54 PM EDT
Active, not recruiting Phase 2 Interventional

An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer

NCT04777071
View directory record Official record
Conditions
Biochemically Recurrent Prostate Carcinoma, Metastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography, Magnetic Resonance Imaging, Bone Scan, Electronic Health Record Review
Procedure · Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 4, 2026, 4:54 PM EDT
Completed Phase 1 Interventional

Exploration of Tumor Accumulation of BAY94-9392 in Patients With Cancer

NCT01186601
View directory record Official record
Conditions
Neoplasms
Interventions
PET tracer (BAY94-9392)
Drug
Lead sponsor
Lantheus Biosciences Ltd.
Industry
Eligibility
18 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2014 · Synced Oct 4, 2026, 4:54 PM EDT
Recruiting Phase 2 Interventional

Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma

NCT06442475
View directory record Official record
Conditions
Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage III Marginal Zone Lymphoma, Ann Arbor Stage IV Follicular Lymphoma, Ann Arbor Stage IV Marginal Zone Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Mosunetuzumab, Positron Emission Tomography, Questionnaire Administration
Procedure · Biological · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 4, 2026, 4:54 PM EDT
Completed Phase 2 Interventional

Study of Individuals With Parkinson's Symptoms But in Whom There is Diagnostic Uncertainty

NCT00129675
View directory record Official record
Conditions
Parkinsonian Syndrome
Interventions
[123I]ß CIT
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
21 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 16, 2014 · Synced Oct 4, 2026, 4:54 PM EDT
Terminated Phase 2 Interventional Results available

[124I]FIAU PET-CT Scanning in Diagnosing Osteomyelitis in Patients With Diabetic Foot Infection

NCT01764919
View directory record Official record
Conditions
Diabetic Foot Infection
Interventions
[124I]FIAU
Radiation
Lead sponsor
BioMed Valley Discoveries, Inc
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Tucson, Arizona • Little Rock, Arkansas • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 8, 2016 · Synced Oct 4, 2026, 4:54 PM EDT
Completed Phase 2 Interventional Results available

Pharmacogenomic & Phase II Study of Gemcitabine and Pemetrexed in Non-Small-Cell Lung Cancer.

NCT00226577
View directory record Official record
Conditions
Lung Cancer
Interventions
Gemcitabine, Pemetrexed, Surgery
Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 4, 2026, 4:54 PM EDT
Completed Phase 3 Interventional Results available

Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer Recurrence

NCT04186845
View directory record Official record
Conditions
Prostate Cancer
Interventions
rhPSMA-7.3 (18F) Injection, Positron emission tomography scan
Drug · Diagnostic Test
Lead sponsor
Blue Earth Diagnostics
Industry
Eligibility
18 Years and older · Male only
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
25
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 4, 2026, 4:54 PM EDT
Completed No phase listed Observational

Brown Fat Activity and White Fat Accumulation

NCT01517581
View directory record Official record
Conditions
Hodgkins Lymphoma, Non-hodgkins Lymphoma
Interventions
Not listed
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
6 Years to 18 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2012 · Synced Oct 4, 2026, 4:54 PM EDT
Recruiting Phase 1Phase 2 Interventional

Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma

NCT07181941
View directory record Official record
Conditions
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Linvoseltamab, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Positron Emission Tomography, Biospecimen Collection
Biological · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 4, 2026, 4:54 PM EDT
Suspended Not applicable Interventional

RefleXion PET/CT Imaging Performance in Patients With Various Malignancies

NCT05844306
View directory record Official record
Conditions
Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
Interventions
Computed Tomography, Fludeoxyglucose F-18, Medical Device Usage and Evaluation, Positron Emission Tomography
Procedure · Other · Device
Lead sponsor
City of Hope Medical Center
Other
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Oct 4, 2026, 4:54 PM EDT
Withdrawn No phase listed Observational

Delayed 18F-FDG PET/CT in Improving Visualization of Brain Tumors in Patients With Glioblastoma

NCT02919332
View directory record Official record
Conditions
Glioblastoma, Glioma
Interventions
Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography
Procedure · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 24, 2020 · Synced Oct 4, 2026, 4:54 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Ga-DOTATATE PET for Phosphaturic Mesenchymal Tumors in Patients With Tumor Induced Osteomalacia

NCT03736564
View directory record Official record
Conditions
Osteomalacia
Interventions
68Ga-DOTATATE PET/CT
Combination Product
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 4, 2026, 4:54 PM EDT
Active, not recruiting Phase 1 Interventional

Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis

NCT05802056
View directory record Official record
Conditions
Clinical Stage IV Gastric Cancer AJCC v8, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Metastatic Gastric Carcinoma, Metastatic Malignant Neoplasm in the Peritoneum
Interventions
Aldesleukin, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Diagnostic Laparoscopy, Fluorouracil, Leucovorin Calcium, Magnetic Resonance Imaging, Nivolumab, Oxaliplatin, Positron Emission Tomography
Biological · Procedure · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 4, 2026, 4:54 PM EDT
Terminated Not applicable Interventional Results available

Sulfur Colloid SPECT/CT in Measuring Liver Function in Patients With Primary or Metastatic Liver Cancer Undergoing Radiation Therapy or Surgery

NCT02881554
View directory record Official record
Conditions
Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Stage IV Liver Cancer, Stage IVA Liver Cancer, Stage IVB Liver Cancer, Vascular Thrombosis
Interventions
Computed Tomography, Single Photon Emission Computed Tomography, Technetium Tc-99m Sulfur Colloid
Procedure · Drug
Lead sponsor
University of Washington
Other
Eligibility
19 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 4, 2026, 4:54 PM EDT
Completed Phase 1 Interventional

Safety Study of Nelfinavir + Cisplatin + Pelvic Radiation Therapy to Treat Cervical Cancer

NCT01485731
View directory record Official record
Conditions
Cervical Cancer
Interventions
Nelfinavir, Cisplatin, Pelvic External Beam Radiation Therapy, Brachytherapy, Pharmacokinetic Sampling, Cervical Biopsy, Pelvic Examination, Pap Smear, Audiogram, Proctoscopy, Cytoscopy, Renal Ultrasound, CT Scan, Whole Body PET/CT Scan
Drug · Radiation · Procedure
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 4, 2026, 4:54 PM EDT
Completed Early Phase 1 Interventional

C-Acetate PET/CT Imaging to Evaluate Treatment Changes in Prostate Cancer

NCT02715583
View directory record Official record
Conditions
Prostate Cancer Patients
Interventions
11C-Acetate
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 18, 2022 · Synced Oct 4, 2026, 4:54 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging

NCT04275453
View directory record Official record
Conditions
Healthy
Interventions
FDG, Ketone Drink, Ketogenetic Diet
Drug · Dietary Supplement · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 16, 2020 · Synced Oct 4, 2026, 4:54 PM EDT
Completed Early Phase 1 Interventional

Copper Cu-64 TP3805 PET/CT in Imaging Patients With Urothelial Cancer Undergoing Surgery or Biopsy

NCT03039413
View directory record Official record
Conditions
Bladder Urothelial Carcinoma, Urothelial Carcinoma
Interventions
Copper Cu 64 TP3805, Positron Emission Tomography, Computed Tomography
Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 4, 2026, 4:54 PM EDT